Image of Lupus in crisis: as failures pile up, clinicians call for new tools

LITERATURE

Lupus in crisis: as failures pile up, clinicians call for new tools


It was another bad year for drug development in lupus. The biggest setback for the field came in late August when AstraZeneca announced that its blockbuster hope anifrolumab, an antibody directed at a subunit of the type I interferon receptor, flunked the first of its two pivotal trials. Then came more bad news when UCB and Biogen reported toward the end of October that their phase 2b study of dapirolizumab pegol, a CD40 ligand–targeted PEGylated antigen-binding fragment, did not meet its primary endpoint either


Availability

REQJ772Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
NATURE BIOTECHNOLOGY VOLUME 37 NUMBER 1 JANUARY 2019
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous